Search results
10 lip 2024 · GENEVA, 10 July 2024— UNAIDS has welcomed the release of Gilead Sciences’ trial results on the injectable long-acting HIV medicine Lenacapavir for HIV prevention. The result “provides hope of accelerating efforts to end AIDS”, UNAIDS says, “but only if Gilead ensures that all people who need it can have access to this game-changing ...
6 mar 2024 · “Longer-acting options relieve the burden of daily pill-taking and have the potential to improve adherence, improve virologic control and reduce new infections.” Lenacapavir, from Gilead Sciences, is the first HIV capsid inhibitor.
17 kwi 2024 · New regimens in development, including once-weekly pills and semiannual shots, could help control the virus in hard-to-reach populations.
4 sty 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
23 gru 2021 · The Food and Drug Administration has approved a new drug in the fight against AIDS. It's the first injectable medication for HIV prevention. NPR's global health correspondent Jason Beaubien...
24 lip 2024 · Two shots a year of a drug currently used to treat HIV infections were dramatically effective at preventing infections in a study among young women and adolescent girls in Africa.
18 lis 2021 · Thousands of people with HIV will now be offered a new long-acting injection to manage their condition if they would prefer to stop taking daily pills. Charities have welcomed the approval of the...
